Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORMAL-R: Non-Operative Management of Rectal Cancer
NCT02641691Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2016
- Primary completion
- Feb 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil, capecitabine in rectal adenocarcinoma, sponsored by Washington University School of Medicine. Started May 2016; status: completed.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02641691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641691.